To include your compound in the COVID-19 Resource Center, submit it here.

AstraZeneca, Daiichi’s trastuzumab ADC sets new efficacy bar in breast cancer

Trastuzumab deruxtecan from AstraZeneca and Daiichi Sankyo may have established a new threshold for efficacy in HER2+ breast cancer based on pivotal Phase II data.

The data were better, in a sicker patient population, than what ADC Kadcyla ado-trastuzumab emtansine demonstrated in the Phase III

Read the full 445 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE